Insights
Search Results
Client Highlights
3.31.26
Wilson Sonsini Advises NexCure on $19 Million Series A Financing
On March 5, 2026, NexCure, a healthcare company with a mission to deliver CAR-T and other clinically intensive treatments in community-based outpatient settings, launched with a $19 million Series A financing. The financing was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures. Wilson Sonsini Goodrich & Rosati advised NexCure on the transaction.
Client Highlights
3.06.26
Wilson Sonsini Advises Cognito Therapeutics on Oversubscribed $105 Million Series C
On March 5, 2026, Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, announced the closing of an oversubscribed $105 million Series C financing round. Wilson Sonsini Goodrich & Rosati advised Cognito Therapeutics on the transaction.
Client Highlights
3.03.26
Wilson Sonsini Advises Versori on Acquisition by Avalara
On February 27, 2026, Avalara, the leading provider of cloud-based tax compliance automation software, announced that it acquired Versori Group, an integration platform company specializing in automated connector development powered by agentic AI. Wilson Sonsini Goodrich & Rosati advised Versori on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises Tenaya Therapeutics on Pricing of Public Offering
On December 11, 2025, Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop, and deliver potentially curative therapies that address the underlying causes of heart disease, announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised Tenaya on the transaction.
Client Highlights
4.09.25
Wilson Sonsini Advises TigaTx on Acquisition by Epsilogen
On April 7, 2025, Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibody therapeutics, announced that it has completed the acquisition of TigaTx, a Boston-based biotechnology company developing engineered immunoglobulin A (IgA) antibodies, to create the world’s leading pan-isotype cancer antibody company.
Client Highlights
12.02.24
Wilson Sonsini Advises Doron Therapeutics on $11 Million Series A
On November 25, 2024, Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, announced it has raised $11 million in a Series A round to take MOTYS™ into Phase 3 clinical studies. SPRIM Global Investments (SGI), a prominent health sciences investment firm, led the round. Wilson Sonsini Goodrich & Rosati advised Doron Therapeutics on the transaction.